Veryan was formed in 2003 as the result of a technology spin out from Imperial College, London, UK. Veryan’s BioMimics 3D technology is based on pioneering research by Professor Colin Caro into the link between blood flow mechanics and vascular disease. Veryan’s primary business focus is the development and commercialisation of novel vascular stent technology arising from this research.1
Veryan benefits from a highly experienced Board of Directors and the Company’s management team has built an outstanding development group, supported by a world class Scientific Advisory Board. The Company’s head office is in Horsham, West Sussex, UK, and the research and development facility is in Galway, Ireland.
Veryan shareholders include: Imperial Innovations Group plc.; National Endowment for Science and Arts (NESTA); Oxford Capital Partners; Seroba Kernel; Seven Mile Capital Partners; management and founders.
1. Caro, C. G. Discovery of the role of wall shear in atherosclerosis. Arterioscler Thromb Vasc Biol 29, 158–61 (2009).